The stock of Biolife Solutions Inc (BLFS) has gone down by -15.32% for the week, with a -2.48% drop in the past month and a -12.75% drop in the past quarter. The volatility ratio for the week is 12.04%, and the volatility levels for the past 30 days are 6.37% for BLFS. The simple moving average for the past 20 days is -5.85% for BLFS’s stock, with a 5.77% simple moving average for the past 200 days.
Is It Worth Investing in Biolife Solutions Inc (NASDAQ: BLFS) Right Now?
Company’s 36-month beta value is 1.87.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLFS is 45.18M, and currently, short sellers hold a 7.75% ratio of that floaft. The average trading volume of BLFS on November 20, 2024 was 349.11K shares.
BLFS) stock’s latest price update
Biolife Solutions Inc (NASDAQ: BLFS) has experienced a rise in its stock price by 9.62 compared to its previous closing price of 20.47. However, the company has seen a fall of -15.32% in its stock price over the last five trading days. prnewswire.com reported 2024-11-14 that Completes the Company’s strategic move away from capital equipment businesses BOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. (“Custom Biogenic Systems” or “CBS”), for $6.1 million in cash.
Analysts’ Opinion of BLFS
Many brokerage firms have already submitted their reports for BLFS stocks, with H.C. Wainwright repeating the rating for BLFS by listing it as a “Buy.” The predicted price for BLFS in the upcoming period, according to H.C. Wainwright is $29 based on the research report published on September 30, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see BLFS reach a price target of $22. The rating they have provided for BLFS stocks is “Buy” according to the report published on April 04th, 2024.
Craig Hallum gave a rating of “Buy” to BLFS, setting the target price at $29 in the report published on July 11th of the previous year.
BLFS Trading at -6.18% from the 50-Day Moving Average
After a stumble in the market that brought BLFS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.30% of loss for the given period.
Volatility was left at 6.37%, however, over the last 30 days, the volatility rate increased by 12.04%, as shares sank -0.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.36% lower at present.
During the last 5 trading sessions, BLFS fell by -15.32%, which changed the moving average for the period of 200-days by +26.57% in comparison to the 20-day moving average, which settled at $23.83. In addition, Biolife Solutions Inc saw 38.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLFS starting from Mathew Aby J., who sale 25,000 shares at the price of $21.17 back on Nov 15 ’24. After this action, Mathew Aby J. now owns 302,046 shares of Biolife Solutions Inc, valued at $529,150 using the latest closing price.
Mathew Aby J., the EVP & Chief Scientific Officer of Biolife Solutions Inc, sale 17,604 shares at $20.05 during a trade that took place back on Nov 18 ’24, which means that Mathew Aby J. is holding 284,442 shares at $352,960 based on the most recent closing price.
Stock Fundamentals for BLFS
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.46 for the gross margin
The net margin for Biolife Solutions Inc stands at -0.37. The total capital return value is set at -0.08. Equity return is now at value -9.87, with -8.19 for asset returns.
Based on Biolife Solutions Inc (BLFS), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -20.73.
Currently, EBITDA for the company is -45.24 million with net debt to EBITDA at -0.71. When we switch over and look at the enterprise to sales, we see a ratio of 8.56. The receivables turnover for the company is 6.88for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.78.
Conclusion
In a nutshell, Biolife Solutions Inc (BLFS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
